Nav: Home

MEK inhibition in KRAS-mutant NSCLC did not improve survival

October 10, 2016

LUGANO-COPENHAGEN, Oct. 10, 2016 - MEK inhibitor selumetinib in combination with docetaxel does not improve progression free or overall survival in individuals with KRAS-mutant non-small-cell lung cancer (NSCLC), according to data presented at the ESMO 2016 Congress in Copenhagen1.

"KRAS-mutant lung cancer is the largest genomically defined subset of lung cancer where we do not have effective targeted therapies," said principal investigator Dr Pasi Jänne, from the Dana-Farber Cancer Institute in Boston, US.

Selumetinib inhibits an effector protein immediately downstream from KRAS, which was thought to turn off KRAS-mediated signalling in KRAS-mutant cancers. An earlier phase II trial in KRAS-mutant NSCLC had shown significant improvements in progression-free survival and objective response rate in patients treated with selumetinib plus docetaxel compared to docetaxel alone. In the phase III, double-blind, randomized SELECT-1 trial, 510 patients with KRAS-mutant non-small-cell lung cancer were randomized either to oral selumetinib (75mg, twice daily) plus intravenous docetaxel (75mg/m2 on day 1 of a 21 day-cycle), or docetaxel plus placebo.

At data cut-off, median progression-free survival was not significantly different between the selumetinib arm and placebo arm (3.9 months vs. 2.8 months, HR 0.93, p=0.44), nor was there a significant difference in median overall survival (8.7 months vs. 7.9 months, HR 1.05, p=0.64). There was a trend towards a higher objective response rate in the selumetinib group compared to the placebo group (20.1% vs. 13.7%, OR 1.61, p=0.051).

Serious adverse events occurred more frequently in patients treated with the selumetinib plus docetaxel combination compared to placebo (49% vs. 32%), as did adverse events leading to hospitalisation (46% vs. 30%). "The results of the phase III trial demonstrate that the addition of selumetinib to docetaxel, in patients with advanced KRAS mutant lung cancer, does not provide clinical benefit in terms of improving progression free or overall survival," Jänne said.

"Hence it is not a treatment approach that should be adapted moving forward, and there remains a desperate need and an opportunity to develop new treatments for this subset of NSCLC patients."

Commenting on the study, Dr Alex Adjei, director of the Early Cancer Therapeutics Program and Global Oncology at the Mayo Clinic in Rochester, US, said "Dr Jänne and colleagues should be congratulated for performing a well-designed genotype-driven trial, however the preclinical rationale for studying this combination specifically in KRAS mutant NSCLC was weak, at best."

"Selumetinib and other MEK inhibitors are not effective in KRAS mutant NSCLC cell lines and, while there are preclinical data that demonstrate cytotoxic synergy between selumetinib and other MEK inhibitors combined with docetaxel in a number of tumor types, including NSCLC, such synergy is independent of KRAS status," Adjei said.

"A randomized phase II trial of the combination of another MEK inhibitor, trametinib and docetaxel failed to show any difference in efficacy between KRAS mutant and wild-type NSCLC. Furthermore, the phase II study on which this phase III trial design was based had a very small sample size and historically, such small randomized phase II studies have led to negative phase III trials," concluded Adjei.
-end-


European Society for Medical Oncology

Related Lung Cancer Articles:

AI helps to fight against lung cancer
Lung cancer has been the leading cause of cancer-related deaths in 2015 in United States.
Free lung-cancer screening in the Augusta area finds more than double the cancer rate of previous screenings
The first year of free lung cancer screening in the Augusta, Ga., area found more than double the rate seen in a previous large, national study as well as a Massachusetts-based screening for this No.
Antioxidants and lung cancer risk
An epidemiological study published in Frontiers in Oncology suggests that a diet high in carotenoids and vitamin C may protect against lung cancer.
Lung cancer may go undetected in kidney cancer patients
Could lung cancer be hiding in kidney cancer patients? Researchers with the Harold C.
Hitgen and Cancer Research UK's Manchester Institute enter license agreement in lung cancer
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.
Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Huntsman Cancer Institute research holds promise for personalized lung cancer treatments
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another.
High levels of estrogen in lung tissue related to lung cancer in postmenopausal women
Researchers from Kumamoto University, Japan have found that postmenopausal women with multicentric adenocarcinoma of the lung have a higher concentration of estrogen in non-cancerous areas of the peripheral lung than similar women diagnosed with single tumor lung cancer.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Pericardial window operation less efficient in cases of lung cancer than any other cancer
Pericardial window operation, a procedure, where abnormal quantity of malignant fluid, surrounding the heart, is drained into the neighbouring chest cavity, is commonly applied to patients diagnosed with cancer.

Related Lung Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Setbacks
Failure can feel lonely and final. But can we learn from failure, even reframe it, to feel more like a temporary setback? This hour, TED speakers on changing a crushing defeat into a stepping stone. Guests include entrepreneur Leticia Gasca, psychology professor Alison Ledgerwood, astronomer Phil Plait, former professional athlete Charly Haversat, and UPS training manager Jon Bowers.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".